Statin-mediated inhibition of RAS prenylation activates ER stress to enhance the immunogenicity of KRAS mutant cancer

Abstract

Our findings suggest that <i>KRAS</i> mutation could be a molecular target for statins to elicit potent tumor-specific immunity.